Castle Biosciences/$CSTL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Castle Biosciences
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Ticker
$CSTL
Sector
Trading on
Industry
Health Care Providers & Services
Headquarters
Employees
784
ISIN
US14843C1053
Website
CSTL Metrics
BasicAdvanced
$461M
-
-$0.18
1.19
-
Price and volume
Market cap
$461M
Beta
1.19
52-week high
$33.33
52-week low
$15.45
Average daily volume
501K
Financial strength
Current ratio
9.374
Quick ratio
8.91
Long term debt to equity
5.291
Total debt to equity
5.87
Interest coverage (TTM)
-23.77%
Management effectiveness
Return on assets (TTM)
-1.79%
Return on equity (TTM)
-1.20%
Valuation
Price to revenue (TTM)
1.289
Price to book
1.04
Price to tangible book (TTM)
1.27
Price to free cash flow (TTM)
10.719
Growth
Revenue change (TTM)
38.43%
Earnings per share change (TTM)
-83.81%
3-year revenue growth (CAGR)
52.37%
3-year earnings per share growth (CAGR)
-55.14%
What the Analysts think about CSTL
Analyst ratings (Buy, Hold, Sell) for Castle Biosciences stock.
CSTL Financial Performance
Revenues and expenses
CSTL Earnings Performance
Company profitability
CSTL News
AllArticlesVideos
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
GlobeNewsWire·19 hours ago
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
GlobeNewsWire·1 week ago
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Castle Biosciences stock?
Castle Biosciences (CSTL) has a market cap of $461M as of May 30, 2025.
What is the P/E ratio for Castle Biosciences stock?
The price to earnings (P/E) ratio for Castle Biosciences (CSTL) stock is 0 as of May 30, 2025.
Does Castle Biosciences stock pay dividends?
No, Castle Biosciences (CSTL) stock does not pay dividends to its shareholders as of May 30, 2025.
When is the next Castle Biosciences dividend payment date?
Castle Biosciences (CSTL) stock does not pay dividends to its shareholders.
What is the beta indicator for Castle Biosciences?
Castle Biosciences (CSTL) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.